About NexImmune
NexImmune is a company based in Gaithersburg (United States) founded in 2011. It operates as a HealthTech. NexImmune has raised $36.27 million across 9 funding rounds from investors including Pfizer, Maryland.gov and HHS. NexImmune offers products and services including AIM™ NT Platform, AIM™ ACT Adoptive Cellular Therapy, and AIM™ INJ Direct Injection. NexImmune operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Gaithersburg, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neximmune, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$32.34 M (USD)48.25as on Dec 31, 2023
-
EBITDA
-$28.17 M (USD)54.26as on Dec 31, 2023
-
Total Equity Funding
$36.27 M (USD)
in 9 rounds
-
Latest Funding Round
$7.77 M (USD), Series A
Feb 22, 2019
-
Investors
Pfizer
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NexImmune
NexImmune is a publicly listed company on the OTC with ticker symbol NEXI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NexImmune
NexImmune offers a comprehensive portfolio of products and services, including AIM™ NT Platform, AIM™ ACT Adoptive Cellular Therapy, and AIM™ INJ Direct Injection.
Platform is developed for targeted immune response modulation.
Therapy is designed for adoptive cellular immune treatment.
Injection is created for direct immune response delivery.
People of NexImmune
Unlock access to complete
Unlock access to complete
Funding Insights of NexImmune
NexImmune has successfully raised a total of $36.27M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $7.77 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NexImmune
NexImmune has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Maryland.gov and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
A venture capital firm focused on healthcare solutions is operated.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for NexImmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NexImmune
Investment portfolio details for NexImmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NexImmune
Detailed financials for NexImmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neximmune Comparisons
Peer comparison for NexImmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NexImmune
NexImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of NexImmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neximmune
Complete news archive for NexImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NexImmune
NexImmune was founded in 2011 and raised its 1st funding round 1 year after it was founded.
NexImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
NexImmune is a funded company, having raised a total of $36.27M across 9 funding rounds to date.
NexImmune is engaged in the development of antigen-directed immunotherapies using its proprietary Artificial Immune Modulation (AIM) nanotechnology platform. The company is involved in creating solutions that orchestrate targeted cell-mediated immune responses across various diseases, including cancer, infectious diseases, and autoimmune disorders. Its technology is customized to either intensify immune responses for treatment of cancer or dampen overactive responses for autoimmune conditions. The AIM platform employs natural biology to deliver specific instructions to T cells, enhancing precision in cell therapy within the healthcare and biotechnology sectors.
NexImmune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
NexImmune offers AIM™ NT Platform, AIM™ ACT Adoptive Cellular Therapy, and AIM™ INJ Direct Injection.
Yes, NexImmune is publicly traded on OTC under the ticker symbol NEXI.
NexImmune has 9 investors. Key investors include Pfizer, Maryland.gov, HHS, ArrowMark Partners, and Piedmont Capital Partners.
The ticker symbol of NexImmune is NEXI on OTC.